ChemoCentryx Presents Data on CCX168, an Orally Administered Small Molecule Inhibitor of C5aR, at the 49th European Renal Association - European Dialysis and Transplant ... - msnbc.com
26 May 2012, 6:45 am
MOUNTAIN VIEW, Calif., May 26, 2012 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (Nasdaq:CCXI), today announced the presentation of results from the Company's development program for CCX168, an investigational orally administered inhibitor of the ...

FDA Panel Sends Mixed Messages on Rare Disease Drug - ABC News
25 May 2012, 5:23 pm
WASHINGTON -- An FDA advisory panel considering an investigational drug to treat a rare nerve disorder agreed that a study of the drug, Vyndaqel, did not provide proof of its benefit. But the panel also agreed that, in this instance, proof may not be necessary.

Data from Study of Elderly Depressed Patients are Reported for investigational Compound Lu AA21004 on Symptoms of Major Depressive Disorder (MDD) - Yahoo Finance
25 May 2012, 2:14 am
PHILADELPHIA, May 8, 2012 /PRNewswire/ -- Today, H. Lundbeck A/S (Lundbeck) and Takeda Pharmaceutical Global Research & Development Center Inc., U.S., presented data which demonstrated significant improvements in overall symptoms of depression ...

XenoPort Submits investigational New Drug Application for XP23829 as a Potential Treatment of RRMS - Yahoo Finance
24 May 2012, 7:23 am
XenoPort, Inc. (XNPT) announced today that it has submitted an investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to begin clinical studies of XP23829 as a potential treatment for relapsing-remitting ...

Millennium and Takeda Announce Presentations for Key investigational Molecules at American Society of Clinical Oncology Annual Meeting - PharmiWeb
23 May 2012, 8:36 am
Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited (TSE:4502) today announced that 101 abstracts featuring the Company’s oncology molecules have been accepted at the annual meeting of the ...

Results from Boehringer Ingelheim’s Respimat Phase II study on moderate, persistent asthma - News-Medical.Net
23 May 2012, 1:33 am
Boehringer Ingelheim announced today results from a Phase II study evaluating the investigational compound tiotropium delivered once-daily via the Respimat ® Inhaler in adolescents with symptomatic, moderate persistent asthma. The data were ...

Celtic Pharma Announces Successful Completion of Phase I/II study of Xerecept® in Pediatric Patients with Cerebral Tumors - Business Wire
22 May 2012, 6:57 am
announces that it has completed a successful Phase I/II study of the investigational new drug Xerecept® (corticorelin acetate) in pediatric patients who are dependent on the steroid Decadron (dexamethasone) to treat peritumoral brain edema associated with ...

PA32540 Cuts Gastric Acid Faster Than Enteric-Coated Aspirin - Medical News Today
20 May 2012, 8:53 am
SAN DIEGO - The investigational compound PA32540 provides faster gastric protection than enteric-coated omeprazole 40 mg, researchers announced at Digestive Disease Week 2012. PA32540 is an investigational coordinated-delivery tablet of ...

Ambit Biosciences and Teva Announce Clearance of an investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor - Genetic Engineering News
17 May 2012, 8:21 am
SAN DIEGO and JERUSALEM, May 17, 2012 /PRNewswire/ -- Ambit Biosciences and Teva Pharmaceutical Industries Limited (NASDAQ: TEVA) ("Teva") today announced the clearance of an investigational New Drug application (IND) with the U.S. Food and Drug ...

TG Therapeutics, Inc. Announces investigational New Drug (IND) for TGTX-1101, Receives Clearance by the FDA to Commence Clinical Trials in the U.S. - GlobeNewsWire (press release)
14 May 2012, 2:58 pm
NEW YORK, May 14, 2012 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (the "Company") - announced today that the U.S. Food and Drug Administration ("FDA") has cleared its investigational New Drug Application ("IND") for TGTX-1101, also known as ublituximab, a ...